Haleon PLC Sponsored ADR $HLN Shares Sold by Keystone Financial Planning Inc.

Keystone Financial Planning Inc. cut its holdings in shares of Haleon PLC Sponsored ADR (NYSE:HLN) by 75.6% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 54,366 shares of the company’s stock after selling 168,476 shares during the period. Keystone Financial Planning Inc.’s holdings in Haleon were worth $550,000 at the end of the most recent reporting period.

A number of other institutional investors have also modified their holdings of the business. First Eagle Investment Management LLC boosted its stake in Haleon by 9.8% during the 3rd quarter. First Eagle Investment Management LLC now owns 3,056,951 shares of the company’s stock worth $27,421,000 after purchasing an additional 273,044 shares during the period. JTC Employer Solutions Trustee Ltd increased its stake in Haleon by 120.7% in the third quarter. JTC Employer Solutions Trustee Ltd now owns 712,229 shares of the company’s stock valued at $6,392,000 after purchasing an additional 389,467 shares during the period. Arlington Partners LLC raised its holdings in shares of Haleon by 128.0% in the third quarter. Arlington Partners LLC now owns 508,886 shares of the company’s stock valued at $4,565,000 after buying an additional 285,692 shares during the last quarter. Archford Capital Strategies LLC purchased a new stake in shares of Haleon in the third quarter valued at about $2,149,000. Finally, New York State Common Retirement Fund acquired a new stake in shares of Haleon during the second quarter worth about $3,964,000. 6.67% of the stock is owned by institutional investors and hedge funds.

Haleon Trading Down 1.5%

NYSE HLN opened at $10.08 on Friday. The stock has a market capitalization of $44.88 billion, a P/E ratio of 25.83 and a beta of 0.18. Haleon PLC Sponsored ADR has a 52-week low of $8.71 and a 52-week high of $11.42. The firm has a 50-day moving average price of $10.53 and a 200 day moving average price of $9.88. The company has a quick ratio of 0.71, a current ratio of 0.92 and a debt-to-equity ratio of 0.47.

Haleon Announces Dividend

The firm also recently disclosed a dividend, which will be paid on Thursday, May 14th. Shareholders of record on Friday, April 10th will be given a $0.1307 dividend. The ex-dividend date is Friday, April 10th. This represents a yield of 251.0%. Haleon’s dividend payout ratio is presently 28.21%.

Analyst Upgrades and Downgrades

A number of research firms recently issued reports on HLN. Weiss Ratings reissued a “hold (c)” rating on shares of Haleon in a report on Thursday, January 22nd. Deutsche Bank Aktiengesellschaft cut Haleon from a “hold” rating to a “sell” rating in a research report on Monday, January 12th. Argus upgraded Haleon to a “strong-buy” rating in a research note on Tuesday. HSBC raised Haleon from a “hold” rating to a “strong-buy” rating in a report on Wednesday, January 21st. Finally, Morgan Stanley reaffirmed an “overweight” rating on shares of Haleon in a report on Monday, December 15th. Two research analysts have rated the stock with a Strong Buy rating, four have given a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $12.33.

Haleon Company Profile

Haleon plc (NYSE:HLN) is a global consumer healthcare company formed through the separation of a large pharmaceutical group’s consumer health business in 2022. Headquartered in the United Kingdom, Haleon develops, manufactures and markets a broad portfolio of over‑the‑counter medicines, oral health products, vitamins, minerals and supplements, and other consumer health goods designed for daily self‑care and symptom relief.

The company’s product mix spans categories such as oral care (toothpastes and sensitivity treatments), pain relief and analgesics, respiratory remedies, digestive health products, topical treatments and nutritional supplements.